Linguistic Validation of the Irritable Bowel Syndrome-Quality of Life Questionnaire for Iranian Patients
There is a growing interest of clinical and epidemiological researches in the field of functional gastrointestinal disorders in our society. Accordingly, validated and culturally adapted instruments are required for appropriate measurement of variables specially the quality of life. The aim of our study was the linguistic validation of the Irritable Bowel Syndrome-Quality of Life questionnaire (IBS-QOL) for Iranian IBS patients with Persian language. Following the standard forward-backward translation method, the IBS-QOL was translated into the Persian language and completed by 141 IBS patients. Patients also completed the IBS Symptom Severity Scale (IBS-SSS) and Hospital Anxiety and Depression Scale (HADS). One-week retest was performed on 30 randomly selected patients. Internal consistency and test-retest reliability were assessed using Cronbach's alpha and intraclass correlation coefficient (ICC), respectively. To analyze the discriminant validity, the IBS-QOL scores was correlated to the IBS-SSS and HADS scores. According to the results, reliability analyses were acceptable for all of the IBS-QOL domains (Cronbach's alpha=0.68 to 0.90 and ICCs=0.77 to 0.91). Discriminant validity was supported by the presence of correlations of the IBS-QOL scores with disease severity (r = -0.628), depression (r = -0.692), and anxiety (r = -0.711) scores; P < 0.001. These results indicate that the Persian version of the IBS-QOL is a reliable instrument with sufficient psychometric requirements to assess quality of life in Iranian IBS patients with Persian language.
Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130(5):1480-91.
Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97(8):1910-15.
Solhpour A, Pourhoseingholi MA, Soltani F, Zarghi, A; Solhpour A, Habibi M, Zali M R. Gastro-oesophageal reflux disease and irritable bowel syndrome: a significant association in an Iranian population. Eur J Gastroenterol Hepatol 2008;20(8):719-25.
Roshandel D, Rezailashkajani M, Shafaee S, Zali MR. A cost analysis of functional bowel disorders in Iran. Int J Colorectal Dis 2006;22(7):791-9.
El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002;16(6):1171-85.
Higginson IJ, Carr AJ. Using quality of life measures in the clinical setting. BMJ 2001;322:1297-1300.
Patrick DL, Drossman DA, Frederick IO, DiCesare J,Puder KL. Quality of life in persons with irritable bowelsyndrome: development and validation of a new measure. Dig Dis Sci 1998;43(2):400-11.
Drossman DA, Patrick DL, Whitehead WE, Toner B B, Diamant N E, Hu Y, Huanguang Jia H, Bangdiwala Sh I. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95(4):999-1007.
Patrick DL, Drossman DA, Frederick IO. A Quality-of- Life Measure for Persons with Irritable Bowel Syndrome (IBS-QOL): User's Manual and Scoring Diskette for United States Version. Washington, DC: University of Washington; 1997.
Park JM, Choi MG, Oh JH, Cho Y K, Lee I S, Kim S W, Choi K Y, Chung I S. Cross-Cultural Validation of Irritable Bowel Syndrome Quality of Life in Korea. Dig Dis Sci 2006;51(8):1478-84.
Huang WW, Zhou FS, Bushnell DM, Diakite C, Yang XH. Cultural adaptation and application of the IBS-QOL in China: a disease-specific quality-of-life questionnaire. Qual Life Res 2007;16(6):991-6.
Kanazawa M, Drossman DA, Shinozaki M, Sagami Y, Yuka Endo, Palsson O S, Hongo M, Whitehead W E,Fukudo Sh. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med 2007;1:6.
Haghayegh A, Kalantari M, Solati K, Molavi H, Adibi P. Study on Validity of Farsi Version of Irritable Bowel Syndrome Quality of Life Questionnaire (IBS-QOL-34). GOVARESH 2008; 13(2): 99-105.
Acquadro C, Conway K, Giroudet C, Mear I. Linguistic validation manual for patient-reported outcomes (PRO)
instruments. Lyon: Mapi Research Institute; 2004.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P. Principles of Good Practice for the Translation and Cultural Adaptation Process forPatient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005;8(2):94-104.
Gordon S, Ameen V, Bagby B, Shahan B, Jhingran P, Carter E. Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci 2003;48(7):1317-23.
Francis CY, Morris J, Whorwell PJ. The irritable bowelseverity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11(2):395-402.
Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003;98(1):122-7.
Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS):translation and validation study of the Iranian version. Health Qual Life Outcomes 2003;1(1):14-9.
Gholamrezaei A, Nemati K, Emami MH. Which end point is more comprehensive in reflecting changes in irritable bowel syndrome treatment trials? Am J Gastroenterol 2009;104(11):2859
Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130(5):1538-51.
|Issue||Vol 49, No 6 (2011)|
|Irritable bowel syndrome Quality of life Reliability Validity|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|